Leucémie à tricholeucocytes

Troussard, 2020, Epidemiology of hairy cell leukemia and HCL-like disorders, Medical Research Archives, 8, 2, 10.18103/mra.v8i10.2259 Wiber M, Maitre E. Poncet JM. A population-based study of hairy cell leukemia over a period of 20 years. Cancer Treat Res Commun 2020;25:100236. doi: 10.1016/j.ctarc.2020.100236. Online ahead of print. Clavel, 1995, Hairy cell leukaemia, occupation, and smoking, British journal of haematology, 91, 154, 10.1111/j.1365-2141.1995.tb05261.x Monnereau, 2014, Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project, JNCI Monographs, 2014, 115, 10.1093/jncimonographs/lgu004 Giné, 2002, Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association? Leukemia, 16, 1454 Obiorah, 2020, Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features, Leuk Lymphoma, 61, 3177, 10.1080/10428194.2020.1797007 Pattnaik, 2020, Atypical presentation of hairy cell leukemia: a report and comprehensive review, Blood Res, 55, 123, 10.5045/br.2020.2020069 Robak, 2020, Bone lesions in hairy cell leukemia: Diagnosis and treatment, Eur J Haematol, 105, 682, 10.1111/ejh.13505 Robak E, Jesionek-Kupnicka D. Robak T. Skin changes in hairy cell leukemia. Ann Hematol. 2020. doi: 10.1007/s00277-020-04349-z. Epub ahead of print. PMID: 33216198. Falini, 2004, Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1), Lancet, 363, 1869, 10.1016/S0140-6736(04)16356-3 Matutes, 1994, The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes, Leuk Lymphoma, 14, 57 Tiacci, 2015, Targeting Mutant BRAF in relapsed or refractory hairy-cell leukemia, N Engl J Med, 373, 1733, 10.1056/NEJMoa1506583 Tschernitz, 2014, Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias, Br J Haematol, 165, 529, 10.1111/bjh.12735 Chung, 2014, Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia, Science Translational Medicine, 6, 238ra71, 10.1126/scitranslmed.3008004 Arons, 2009, VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy, Blood, 114, 4687, 10.1182/blood-2009-01-201731 Xi, 2012, Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation, Blood, 119, 3330, 10.1182/blood-2011-09-379339 Jain, 2016, Relapsed Refractory BRAF Negative, IGHV 4-34–positive variant of hairy cell leukemia: A Distinct Entity? JCO, 34, e57 Forconi, 2009, Hairy cell leukemias with unmutated IGHV genes define the minorsubset refractory to single agent cladribine and with more aggressive behavior, Blood, 114, 4696, 10.1182/blood-2009-03-212449 Forconi, 2011, Hairy cell leukaemia: biological and clinical overview from immunogenetic insights, Hematol Oncol, 29, 55, 10.1002/hon.975 Else, 2015, Long-term follow-up after purine analogue therapy in hairy cell leukaemia, Best Pract Res Clin Haematol, 28, 217, 10.1016/j.beha.2015.09.004 Cornet, 2014, Société française d’hématologie, Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol, 166, 390 Paillassa, 2020, Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up, Blood Cancer J, 10, 62, 10.1038/s41408-020-0328-z Maloisel, 2003, Long-term outcome with pentostatin treatment in hairy cell leukemia patients, A French retrospective study of 238 patients. Leukemia, 17, 45 Grever, 2017, Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia, Blood, 129, 553, 10.1182/blood-2016-01-689422 Ravandi, 2011, Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia, Blood, 118, 3818, 10.1182/blood-2011-04-351502 Chihara, 2016, Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial, Br J Haematol, 174, 760, 10.1111/bjh.14129 Chihara, 2020, Randomized phase II study of first-Line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia, J Clin Oncol, 38, 1527, 10.1200/JCO.19.02250 Akarca, 2013, BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia, Br J Haematol, 162, 848, 10.1111/bjh.12429 Garnache Ottou, 2014, Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients, Br J Haematol, 166, 50, 10.1111/bjh.12839 Troussard X, Grever MR. The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant. Br J Haematol. 2020. doi: 10.1111/bjh.17201. Epub ahead of print. PMID: 33368172. Kreitman, 2018, Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, Leukemia, 32, 1768, 10.1038/s41375-018-0210-1 Tiacci, 2015, Targeting mutant BRAF in relapsed or refractory Hairy-Cell Leukemia, N Engl J Med, 373, 1733, 10.1056/NEJMoa1506583 Dietrich, 2016, BRAF inhibition in hairy cell leukemia with low-dose vemurafenib, Blood, 127, 2847, 10.1182/blood-2015-11-680074 Liebers, 2020, BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials, Leukemia, 34, 1454, 10.1038/s41375-019-0646-y Callahan, 2012, Progression of RAS-mutant leukemia during RAF inhibitor treatment, N Engl J Med, 367, 2316, 10.1056/NEJMoa1208958 Yaktapour, 2014, BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia, J Clin Invest, 124, 5074, 10.1172/JCI76539 Simnica D, Ittrich H. Bockemeyer C et al. Targeting the mutational landscape of bystander cells: drug-promoted blood cancer from high-prevalence pre-neoplasias in patients on BRAF inhibitors. Front Oncol. 2020;10:540030. doi: 10.3389/fonc.2020.540030. PMID: 33042833; PMCID: PMC7517330. Troussard, 1994, Hairy cell leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment, Leuk Lymphoma, 14, 99 Burotto, 2013, Bendamustine and rituximab in relapsed and refractory hairy cell leukemia, Clin Cancer Res, 19, 6313, 10.1158/1078-0432.CCR-13-1848 Jain, 2018, Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax, Am J Hematol, 93, 1568, 10.1002/ajh.25264